Valneva SE, a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today it will present on its Lyme disease and chikungunya vaccine candidates on April 16th, 2019 at the 19th World Vaccine Congress in Washington, D.C.
Valneva’s Chief Executive Officer, Thomas Lingelbach, will provide an update and discuss next steps for VLA15, the Company’s vaccine candidate against Lyme disease. Lyme is the most commonly occurring vector borne illness in the Northern Hemisphere with an estimated 300,000 Americans contracting the disease each year. VLA15 has been shortlisted in the “Best Prophylactic Vaccine” category of the 2019 Vaccine Industry Excellence (ViE) Awards, held in conjunction with the World Vaccine Congress each year.
Valneva’s Chief Medical Officer, Dr. Wolfgang Bender, will also present on the Phase 1 development of the Company’s chikungunya vaccine candidate, VLA1553. He will also discuss next steps for the potential single-shot vaccine.
Valneva, a gold sponsor of the event, will have a display in the exhibit area at booth #318.
Event: The World Vaccine Congress 2019, Washington, D.C.
Venue: Renaissance Washington D.C. Downtown Hotel
Date: Tuesday, April 16, 2019
Time: 11:40 a.m. EDT for the chikungunya presentation; 2:40 p.m. EDT for the Lyme presentation